Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study

Hassan Abolghasemi, Peyman Eshghi, Abdol Majid Cheraghali, Abbas Ali Imani Fooladi, Farzaneh Bolouki Moghaddam, Sina Imanizadeh, Matin Moeini Maleki, Mohammad Ranjkesh, Mohammad Rezapour, Ali Bahramifar, Behzad Einollahi, Mohammad Javad Hosseini, Nematollah Joneidi Jafari, Mohamad Nikpouraghdam, Nariman Sadri, Mokhtar Tazik, Shanaz Sali, Shamsi Okati, Elham Askari, Payam Tabarsi, Jafar Aslani, Ehsan Sharifipour, Mohammad Hossein Jarahzadeh, Nastaran Khodakarim, Mahmood Salesi, Ramezan Jafari, Samira Shahverdi, Hassan Abolghasemi, Peyman Eshghi, Abdol Majid Cheraghali, Abbas Ali Imani Fooladi, Farzaneh Bolouki Moghaddam, Sina Imanizadeh, Matin Moeini Maleki, Mohammad Ranjkesh, Mohammad Rezapour, Ali Bahramifar, Behzad Einollahi, Mohammad Javad Hosseini, Nematollah Joneidi Jafari, Mohamad Nikpouraghdam, Nariman Sadri, Mokhtar Tazik, Shanaz Sali, Shamsi Okati, Elham Askari, Payam Tabarsi, Jafar Aslani, Ehsan Sharifipour, Mohammad Hossein Jarahzadeh, Nastaran Khodakarim, Mahmood Salesi, Ramezan Jafari, Samira Shahverdi

Abstract

Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients' need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy.

Keywords: COVID-19; Clinical trial; Convalescent plasma; Hospital stay; Mortality rate.

Copyright © 2020 Elsevier Ltd. All rights reserved.

References

    1. Abdi M. Coronavirus disease 2019 (COVID-19) outbreak in Iran: actions and problems. Infect Control Hosp Epidemiol. 2020:1–2. doi: 10.1017/ice.2020.86.
    1. Cheng Y., Wong R., Soo Y.O., Wong W.S., Lee C.K., Ng M.H.L. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–46.
    1. Soo Y.O., Cheng Y., Wong R., Hui D.S., Lee C.K., Tsang K.K.S. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10:676–678.
    1. Luke T.C., Kilbane E.M., Jackson J.L., Hoffman S.L. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145:599–609.
    1. Cheng Y., Wong R., Soo Y.O. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–46.
    1. Arabi Y.M., Hajeer A.H., Luke T., Yaseen M., Raviprakash K., Balkhy H. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg. Infect. Dis. 2016;22:1554–1561.
    1. Bloch E.M., Shoham S., Casadevall A. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;7
    1. Rojas M., Rodriguez Y., Monsalve D.M., Acosta-Ampudia Y., Camacho B., Esteban Gallo J. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020;4 doi: 10.1016/j.autrev.2020.102554.
    1. Cheraghali A.M., Abolghasemi H., Eshghi P. Management of COVID-19 virus infection by convalescent plasma; Iran J Allergy Asthma Immunol. 2020 In press.
    1. Sullivan H.C., Roback J.D. Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic. Transfus Med Rev. 2020 doi: 10.1016/j.tmrv.2020.04.001. pii: S0887-7963(20)30025-0.
    1. Casadevall A., Pirofski L.A. The convalescent sera option for containing COVID -19. J Clin Invest. 2020 doi: 10.1172/JCI138003.
    1. Roback J.D., Guarner J. Convalescent plasma to treat COVID -19: possibilities and challenges. JAMA. 2020 doi: 10.1001/jama.2020.4940.
    1. Langhi D.M., Santis G.C., Bordin J.O. COVID-19 convalescent plasma transfusion. Hematol Transfus Cell Ther. 2020 doi: 10.1016/j.htct.2020.04.003.
    1. Zhao J., Yuan Q., Wang H., Liu W., Liao X., Su Y. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa344. ciaa344.
    1. Ye M., Fu D., Ren Y., Wang F., Wang D., Zhang F. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020 doi: 10.1002/jmv.25882.
    1. Shen C., Wang Z., Zhao F., Yang Y., Li J., Yuan J. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. doi: 10.1001/jama.2020.4783.
    1. Duan K., Liu B., Li C., Zhang H., Yu T., Qu J. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020 pii: 202004168.
    1. Ahn J.Y., Sohn Y., Lee S.H., Cho Y., Hoon Hyun J., Jee Baek Y. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci. 2020;35(14) doi: 10.3346/jkms.2020.35.e149. e149. 2020.
    1. Recommendations for Investigational COVID-19 Convalescent Plasma .
    1. An EU programme of COVID-19 convalescent plasma collection and transfusion .
    1. Joyner J.M., Wright R.S., Fairweather D., Senefeld J.W., Bruno K., Klassen S. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. MedRxIv. 2020 Posted May 14.
    1. Tiberghien P., Lamballerie X., Morel P., Gallian P., Lacombe K., Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. 2020 doi: 10.1111/vox.12926.
    1. Pan F., Ye T., Sun P., Gui S., Liang B., Li L. Time course of lung changes on chest CT during recovery from 2019 novel Coronavirus (COVID-19) pneumonia. Radiology. 2020;(13) doi: 10.1172/JCI138745. 200370.
    1. Nikpouraghdam M., Jalali Farahani A., Alishiri G.H., Heydari S., Ebrahimnia M., Samadinia H. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: a single center study. J Clin Virol. 2020;(127) 104378.
    1. Fleming A.B., Raabe V. Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement. J Clin Virol. 2020;28(127) doi: 10.1016/j.jcv.2020.104388. 104388.
    1. Arentz M., Yim E., Klaff L., Lokhandwala S., Riedo F.X., Chong M. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323:1612–1614.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit